Last update 21 Nov 2024
Recombinant anti-HER2 humanized HuA21 monoclonal antibody(Hefei Hankemab Biotechnology Co Ltd)
Last update 21 Nov 2024
Overview
Basic Info
Drug Type Monoclonal antibody |
Synonyms- |
Target |
Mechanism HER2 antagonists(Receptor protein-tyrosine kinase erbB-2 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
2
Clinical Trials associated with Recombinant anti-HER2 humanized HuA21 monoclonal antibody(Hefei Hankemab Biotechnology Co Ltd)评价重组抗 HER2 人源化 HuA21 单克隆抗体注射液联合曲妥珠单抗联合化疗治疗 HER2阳性局部晚期/转移性胃癌患者的Ⅰb/Ⅱ期临床研究
[Translation] A phase Ib/II clinical study to evaluate the combination of recombinant anti-HER2 humanized HuA21 monoclonal antibody injection with trastuzumab and chemotherapy in the treatment of patients with HER2-positive locally advanced/metastatic gastric cancer
评价重组抗 HER2人源化 HuA21单克隆抗体注射液治疗 HER2 阳性晚期恶性实体肿瘤的安全性、耐受性和药代动力学特征的 I 期临床研究
[Translation] A phase I clinical study to evaluate the safety, tolerability and pharmacokinetic characteristics of recombinant anti-HER2 humanized HuA21 monoclonal antibody injection in the treatment of HER2-positive advanced malignant solid tumors
100 Clinical Results associated with Recombinant anti-HER2 humanized HuA21 monoclonal antibody(Hefei Hankemab Biotechnology Co Ltd)
Login to view more data
100 Translational Medicine associated with Recombinant anti-HER2 humanized HuA21 monoclonal antibody(Hefei Hankemab Biotechnology Co Ltd)
Login to view more data
100 Patents (Medical) associated with Recombinant anti-HER2 humanized HuA21 monoclonal antibody(Hefei Hankemab Biotechnology Co Ltd)
Login to view more data
1
Literatures (Medical) associated with Recombinant anti-HER2 humanized HuA21 monoclonal antibody(Hefei Hankemab Biotechnology Co Ltd)01 Jan 2023American journal of cancer research
A novel 4-1BB/HER2 bispecific antibody shows potent antitumor activities by increasing and activating tumor-infiltrating T cells.
Article
Author: Liu, Wenting ; Shen, Guodong ; Wang, Mengli ; Zhao, Qun ; Zhang, Dayan ; Fang, Qing ; Li, Yongxiang ; Wang, Huizhen ; Zeng, Xiaoli ; Shen, Aolin ; Wang, Fengrong ; Cheng, Liansheng
100 Deals associated with Recombinant anti-HER2 humanized HuA21 monoclonal antibody(Hefei Hankemab Biotechnology Co Ltd)
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| HER2-positive gastric cancer | Phase 2 | CN | 25 Mar 2024 | |
| HER2 Positive Solid Tumors | Phase 1 | CN | 19 Jul 2021 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free